Bioenvision to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
09 Avril 2007 - 1:02PM
Business Wire
Bioenvision, Inc. (Nasdaq:BIVN) today announced Christopher B.
Wood, M.D., chairman and chief executive officer of the Company,
will be giving a presentation at the CIBC World Markets Annual
Biotechnology & Specialty Pharmaceuticals Conference on
Thursday, April 12, 2007 at 2:30pm EDT. The conference is being
held at the Millennium Broadway hotel in New York City. The
presentation will be webcast live and available on the webcast
section of the Company�s website, www.bioenvision.com. The webcast
will be archived and the link will remain active through April 26,
2007. About Bioenvision Bioenvision's primary focus is the
acquisition, development and marketing of compounds and
technologies for the treatment of cancer. Bioenvision has a broad
pipeline of products for the treatment of cancer, including:
Evoltra�, Modrenal� (for which Bioenvision has obtained regulatory
approval for marketing in the United Kingdom for the treatment of
post-menopausal breast cancer following relapse to initial hormone
therapy), and other products. Bioenvision is also developing Suvus�
which is currently in clinical development for refractory chronic
hepatitis C infection. For more information on Bioenvision please
visit our website at www.bioenvision.com. Certain statements
contained herein are "forward-looking" statements (as such term is
defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Specifically, factors that could
cause actual results to differ materially from those expressed or
implied by such forward-looking statements include, but are not
limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the
potential failure of Bioenvision's compounds under development to
prove safe and effective for treatment of disease; uncertainties
inherent in the early stage of Bioenvision's compounds under
development; failure to successfully implement or complete clinical
trials; failure to receive marketing clearance from regulatory
agencies for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic initiatives that
change Bioenvision's business, structure or projections; the
development of competing products; uncertainties related to
Bioenvision's dependence on third parties and partners; and those
risks described in Bioenvision's filings with the SEC. Bioenvision
disclaims any obligation to update these forward-looking
statements.
Bioenvision (NASDAQ:BIVN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Bioenvision (NASDAQ:BIVN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Bioenvision (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Bioenvision, Inc.